Predict your next investment

Corporation
norgine.com

See what CB Insights has to offer

Portfolio Exits

1

Partners & Customers

10

About Norgine

Norgine provides expertise and 'know how' in Europe to develop, commercialize and manufacture products that offer real value to payers, healthcare professionals and patients.

Norgine Headquarter Location

Hogehilweg 7

Amsterdam, 1101,

Netherlands

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Norgine News

New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients

Oct 4, 2021

10/04/2021 | 07:01am EDT Message : *Required fields ZUG, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Covis Pharma GmbH (“Covis”) and Norgine B.V. (“Norgine”) today announced data demonstrating the investigational anticoagulant reversal agent, ciraparantag, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly patients, were published in the European Heart Journal , official journal of the European Society of Cardiology. “This Phase 2a study demonstrates that ciraparantag rapidly and effectively reverses the anticoagulant activity of the most commonly used direct oral anticoagulants, apixaban and rivaroxaban,” said lead author Dr. Jack Ansell, professor of medicine, Hofstra Northwell School of Medicine. “The reversal was sustained and without important side effects suggesting that ciraparantag has the potential to fill an important gap in our ability to treat major bleeding, a not uncommon occurrence with these anticoagulants.” Ciraparantag produced a rapid and dose-related reversal of anticoagulation induced by apixaban and rivaroxaban compared with placebo in two dose ranging studies in healthy elderly adults (age 50-75 years). Anticoagulation was completely reversed within 1-hour post-dose and was sustained through 5 hours (for apixaban) and 6 hours (for rivaroxaban). Ciraparantag provided a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban. In these two randomized, single-blind, placebo-controlled Phase 2 clinical trials, ciraparantag was well tolerated across the range of doses evaluated and shown to be safe. The most common adverse events were mild, transient sensations of warmth or flushing and were dose related. “These data provide further support for the potential value that ciraparantag offers as a broad-spectrum, conveniently dosed, rapid-acting anticoagulant reversal agent,” said Raghav Chari, PhD, chief innovation officer of Covis. “We look forward to continuing the development of ciraparantag in the various studies we are planning.” Christopher Bath, chief operating officer of Norgine, continued, “Our commitment to transforming patients’ lives drives everything we do at Norgine and we are delighted to be working with Covis to support the development of ciraparantag.” About Ciraparantag Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Target patient populations include patients for whom rapid reversal of anticoagulation is needed because of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures. It is believed that ciraparantag exerts its effects by binding to and blocking the effects of a number of DOACs such as Xarelto® (rivaroxaban), Eliquis® (apixaban) and Lixiana / Savaysa® (edoxaban), as well as to the LMWH Lovenox® (enoxaparin sodium injection), which in turn reestablishes normal clot formation. Ciraparantag is administered by intravenous infusion; the anticipated clinical treatment regimen is a single dose administered over approximately 10 minutes. Ciraparantag has been studied across seven completed trials, with more than 270 subjects having been dosed with ciraparantag and has been well tolerated in these studies. To date, the most common adverse events related to ciraparantag have been mild transient sensations of warmth or skin flushing, skin tingling, and alterations in taste. The safety and efficacy of ciraparantag is under investigation through the ongoing clinical development program, and ciraparantag is not approved for use by the FDA or any other regulatory authority. About Covis Covis, with global operations in Zug, Switzerland, is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Additional information is available at www.covispharma.com . About Norgine Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Norgine is proud to have helped 22 million patients around the world in 2020 and generated €448 million in net product sales, a growth of 7% over 2019. Additional information is available at www.norgine.com . Trademarks are the property of their respective owners. Media Contacts

Norgine Portfolio Exits

1 Portfolio Exit

Norgine has 1 portfolio exit. Their latest portfolio exit was Arc Medical Design on August 07, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/7/2020

Acquired

4

Date

8/7/2020

Exit

Acquired

Companies

Valuation

Acquirer

Sources

4

Norgine Acquisitions

3 Acquisitions

Norgine acquired 3 companies. Their latest acquisition was Azanta on March 25, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/25/2020

Other Venture Capital

$99M

$8.87M

Acquired

1

7/17/2017

Subscribe to see more

$99M

Subscribe to see more

10

4/2/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/25/2020

7/17/2017

4/2/2015

Investment Stage

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$8.87M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Norgine Partners & Customers

10 Partners and customers

Norgine has 10 strategic partners and customers. Norgine recently partnered with US WorldMeds on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/23/2021

Licensor

US WorldMeds

United States

Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand

Amsterdam , Netherlands and Louisville , Ky. - NORGINE B.V. a leading European specialist pharmaceutical company and US WorldMeds , a Kentucky-based specialty pharmaceutical company , today announced an exclusive licensing agreement by which Norgine Ventures will register and commercialise difluoromethylornithine , DFMO in Europe , Commonwealth of Independent States , Australia and New Zealand .

1

7/23/2020

Licensor

AMAG Pharmaceuticals

United States

AMAG Pharmaceuticals And Norgine B.V. Enter Into Exclusive Licensing Agreement To Commercialize Ciraparantag In Europe, Australia And New Zealand

WALTHAM , Mass. and AMSTERDAM , The Netherlands , July 23 , 2020 -- AMAG Pharmaceuticals , Inc. - Get Report and Norgine , a leading European specialist pharmaceutical company , today announced they have entered into an exclusive licensing agreement to develop and commercialize ciraparantag in Europe , Australia and New Zealand .

6

3/25/2019

Licensee

Olympus Corporation of the Americas

United States

Olympus Corporation of the Americas Enters into US and Canada Distribution Agreement with Arc Medical Design Ltd., a Subsidiary of Norgine for ENDOCUFF VISION® Olympus Corporation of the Americas Enters into US and Canada Distribution Agreement with Arc Medical Design Ltd., a Subsidiary of Norgine for ENDOCUFF VISION®.

`` We are pleased to strengthen our commercial strategy through this relationship with Arc Medical Design Ltd. , '' said Christos Monovoukas , VP , Business Development and Strategy at Olympus `` This agreement represents a significant market opportunity for the Olympus Corporation of the Americas endoscopy business and an important advantage for our customers and their patients . ''

1

3/5/2019

Licensor

Noventure

Spain

Subscribe to see more

Subscribe to see more

10

1/3/2019

Licensee

Korea Pharma

South Korea

Subscribe to see more

Subscribe to see more

10

Date

7/23/2021

7/23/2020

3/25/2019

3/5/2019

1/3/2019

Type

Licensor

Licensor

Licensee

Licensor

Licensee

Business Partner

US WorldMeds

AMAG Pharmaceuticals

Olympus Corporation of the Americas

Noventure

Korea Pharma

Country

United States

United States

United States

Spain

South Korea

News Snippet

Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand

Amsterdam , Netherlands and Louisville , Ky. - NORGINE B.V. a leading European specialist pharmaceutical company and US WorldMeds , a Kentucky-based specialty pharmaceutical company , today announced an exclusive licensing agreement by which Norgine Ventures will register and commercialise difluoromethylornithine , DFMO in Europe , Commonwealth of Independent States , Australia and New Zealand .

AMAG Pharmaceuticals And Norgine B.V. Enter Into Exclusive Licensing Agreement To Commercialize Ciraparantag In Europe, Australia And New Zealand

WALTHAM , Mass. and AMSTERDAM , The Netherlands , July 23 , 2020 -- AMAG Pharmaceuticals , Inc. - Get Report and Norgine , a leading European specialist pharmaceutical company , today announced they have entered into an exclusive licensing agreement to develop and commercialize ciraparantag in Europe , Australia and New Zealand .

Olympus Corporation of the Americas Enters into US and Canada Distribution Agreement with Arc Medical Design Ltd., a Subsidiary of Norgine for ENDOCUFF VISION® Olympus Corporation of the Americas Enters into US and Canada Distribution Agreement with Arc Medical Design Ltd., a Subsidiary of Norgine for ENDOCUFF VISION®.

`` We are pleased to strengthen our commercial strategy through this relationship with Arc Medical Design Ltd. , '' said Christos Monovoukas , VP , Business Development and Strategy at Olympus `` This agreement represents a significant market opportunity for the Olympus Corporation of the Americas endoscopy business and an important advantage for our customers and their patients . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

6

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.